Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACE-083 in healthy postmenopausal women
NCT02257489Phase 1Completed
- Start
- Sep 2014
- Primary completion
- Mar 2016
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of efmitermant alfa in facioscapulohumeral muscular dystrophy (FSHD) and Charcot-Marie-Tooth disease (CMT) (7 arms). Primary endpoint: Number of Subjects With Adverse Events. Started Sep 2014; status: completed.
02
Drugs
efmitermant alfa
03
Conditions
facioscapulohumeral muscular dystrophy (FSHD)Charcot-Marie-Tooth disease (CMT)
Beyond the preview
Go deeper on NCT02257489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02257489.